Clinical Trial

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

Name: An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS — clinical trial record (NCT07665437)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.

Trial Details

NCT Number	NCT07665437
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Hidradenitis Suppurativa
Enrollment	710 participants
Start Date	2026-07-09
Primary Completion	2031-10-27 (estimated)
Study Completion	2031-10-27 (estimated)
Updated on ClinicalTrials.gov	2026-06-24